Tracer library / [90Y]Y-pentixather
[90Y]Y-pentixather
Also written as Pentixather; pentixather; [Y-90]Pentixather; PentixaTher; [Y-90]Y-PentixaTher
- Radionuclide
- Y-90 t½ 3843.6 min
- Modality
- Therapy
- Production route
- —
- Stage
- —
- Syntheses indexed
- 0
What it is
- Compound class
- Pentixather (CXCR4-targeted radiolabelled peptide)
- Target / mechanism
- CXCR4 (chemokine receptor-4) PMID 28529638
- Clinical application
- CXCR4-directed endoradiotherapy in relapsed/refractory hematologic malignancies (multiple myeloma, acute leukemia) prior to hematopoietic stem cell transplantation PMID 30850502
- Theranostic pair
- —
Published syntheses
No synthesis has been parsed for this agent yet.
Clinical literature
Clinical studies in the indexed corpus, ordered by design (multicentre, prospective, retrospective, others, case reports last) and then by year. Titles and links only, as published; this is not a summary of the evidence.
- Side Effects of CXC-Chemokine Receptor 4-Directed Endoradiotherapy with Pentixather Before Hematopoietic Stem Cell Transplantation.2019 · J Nucl Med · Retrospective
- Myeloablative Radioligand Therapy Targeting C-X-C Motif Chemokine Receptor 4 in Advanced Multiple Myeloma.2025 · Clin Nucl Med · Clinical study
- First-in-Human Experience of CXCR4-Directed Endoradiotherapy with 177Lu- and 90Y-Labeled Pentixather in Advanced-Stage Multiple Myeloma with Extensive Intra- and Extramedullary Disease.2016 · J Nucl Med · Clinical study
Need this precursor?We can point you to suppliers for [90Y]Y-pentixather, or handle the enquiry for you.
Get in touchNotes
Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 3 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 29290814: 'Synthesis of Pentixafor and Pentixather'. | Stage 28: added indication(s) onc-myeloma, onc-leukemia from consolidated missing-rubric review.